Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach.

Human gene therapy·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

Capsid-engineered AAV vector overcomes a key intracellular barrier and efficiently transduces spiral ganglion neurons in adult mice.

Molecular therapy. Advances·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

Therapeutic antibody delivery: vector tools to boost efficacy and affordability.

Frontiers in immunology·2026
Same author

Robust Functionality and Regulation of Selectively Expressed RNA as AAV Vectors and In Vitro Transcribed Molecules.

Pharmaceutics·2025

Related Experiment Video

Updated: May 20, 2026

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform
05:51

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

Published on: May 3, 2024

Optimizing the adeno-associated viral vector system: a brief summary.

Ulrich Hacker, Hildegard Büning

    Therapeutic Delivery
    |July 25, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Recombinant adeno-associated virus (rAAV) vectors are leading gene transfer systems due to their safety and stability. Ongoing research optimizes rAAV vectors for enhanced gene therapy applications by improving capsid and genome design.

    More Related Videos

    Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
    09:12

    Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

    Published on: April 5, 2024

    Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications
    03:52

    Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications

    Published on: February 9, 2024

    Related Experiment Videos

    Last Updated: May 20, 2026

    A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform
    05:51

    A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

    Published on: May 3, 2024

    Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
    09:12

    Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

    Published on: April 5, 2024

    Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications
    03:52

    Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications

    Published on: February 9, 2024

    Area of Science:

    • Gene therapy
    • Molecular biology
    • Virology

    Background:

    • Recombinant adeno-associated virus (rAAV) vectors are prominent tools for gene transfer in research and clinical settings.
    • Key advantages include nonpathogenicity, high stability, and low immunogenicity, making them suitable for therapeutic applications.

    Discussion:

    • Production methods for rAAV vectors have been streamlined.
    • The vector platform is expanding through alternative serotypes and engineered capsids (mosaic, hybrid).

    Key Insights:

    • rAAV vector efficacy is being enhanced by a deeper understanding of virus-host interactions.
    • Optimization efforts focus on both the vector's capsid and its genetic payload (genome).

    Outlook:

    • Further advancements in capsid engineering and genome design promise to overcome current limitations.
    • Continued development aims to broaden the scope and effectiveness of rAAV-based gene therapies.